Блог – Bioequivalence.design

Bioequivalence.design | PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Найти:

Свежие записи

Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0
ClinicalTrialUtilities: обзор
Подборка полезной литературы – часть 2

Галерея

UPDATED TIME INFORMATION: November 4, 2021: Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting Announcement - 11/04/2021
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-20 By FDA
Generic Drug Facilities, Sites and Organization Lists
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-20 By FDA
What's New Related to Drugs
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-20 By FDA
Alma LeVant Hayden's Contributions to Regulatory Science
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-20 By FDA
Human medicines European public assessment report (EPAR): Movymia, teriparatide, Osteoporosis, Date of authorisation: 11/01/2017, Revision: 10, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-20
Human medicines European public assessment report (EPAR): Fasenra, benralizumab, Asthma, Date of authorisation: 08/01/2018, Revision: 7, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-20
Human medicines European public assessment report (EPAR): Zynteglo, betibeglogene autotemcel, beta-Thalassemia, Date of authorisation: 29/05/2019, Revision: 5, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-20
Human medicines European public assessment report (EPAR): Neulasta, pegfilgrastim, Neutropenia;Cancer, Date of authorisation: 22/08/2002, Revision: 37, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-20
Human medicines European public assessment report (EPAR): Forsteo, teriparatide, Osteoporosis;Osteoporosis, Postmenopausal, Date of authorisation: 10/06/2003, Revision: 24, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-20
Drug Safety Communications
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-20 By FDA
Human medicines European public assessment report (EPAR): COVID-19 Vaccine Janssen, COVID-19 vaccine (Ad26.COV2-S [recombinant]), COVID-19 virus infection, Date of authorisation: 11/03/2021, Revision: 16, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-20
Human medicines European public assessment report (EPAR): Plavix, clopidogrel, Stroke;Peripheral Vascular Diseases;Atrial Fibrillation;Myocardial Infarction;Acute Coronary Syndrome, Date of authorisation: 15/07/1998, Revision: 45, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-20
Blood Grouping and Phenotyping Reagents
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-01-20 By FDA
Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Postmenopause, Date of authorisation: 08/01/2018, Revision: 5, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-01-20
Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
Source: FDA - What's New: Drugs RSS Feed Published on 2022-01-20 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.